Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company, which engages in the development of organ implants to treat congenital defects, cancers, and life-threatening conditions of the esophagus, bronchus and trachea. The company is headquartered in Holliston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2013-10-14. The firm's technology is based on its cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. The firm is advancing its Cellspan esophageal implant product candidate through an Investigator-Initiated Trial targeting pediatric patients with Esophageal Atresia. Its biocompatible scaffold component of its esophageal implant is constructed primarily of thin polyurethane fibers. Its other product candidates in development pipeline are targeted at the reconstruction of the colon and uterus wound repair. The Company, through its subsidiary, Harvard Apparatus Regenerative Technology Limited, is focused on personal healthcare, including dietary supplements.